Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients

Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients
Clovis Oncology plans to apply to the U.S. Food and Drug Administration (FDA) for expanded approval of Rubraca (rucaparib) as a second-line and later maintenance treatment for all women with ovarian cancer who have responded to their latest treatment with platinum chemotherapy. The decision came with the company’s announcement of positive outcomes of a Phase

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *